SANDRA PULLEN: Open Payments
NPI 1053895706 · TUCSON, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,083 in 51 payments from 13 companies in 2025. Trend: 2023 $1,044 · 2024 $1,047 · 2025 $1,083
Food & beverage: $1,083
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 11 | $268 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $232 |
| GENZYME CORPORATION | 2 | $155 |
| Aimmune Therapeutics, Inc. | 18 | $140 |
| ABBVIE INC. | 4 | $65 |
| Enterra Medical, Inc. | 1 | $52 |
| Madrigal Pharmaceuticals | 2 | $42 |
| Novo Nordisk Inc | 1 | $24 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $23 |
| Phathom Pharmaceuticals, Inc. | 1 | $22 |
Products named: TREMFYA, ENTYVIO, DUPIXENT, ZENPEP, REZDIFFRA, RINVOQ, LINZESS, Wegovy.
Industry payments across AZ — which companies pay providers there.
